Advanced NK Cell Engineering Platforms
Creative Biolabs offers cutting-edge platforms to enhance CAR-NK cell therapies, providing innovative solutions for cancer immunotherapy. Our proprietary technologies leverage NK cell biology to create more effective, safer therapeutic options with reduced side effects compared to traditional approaches. Explore our comprehensive suite of NK cell engagement platforms designed to overcome the limitations of current immunotherapy strategies.
ROCK™ Antibody Platform
The ROCK™ platform represents our most advanced NK cell engagement technology. Utilizing high-affinity anti-CD16A antibodies that target unique epitopes, this platform offers reduced competitive binding and activates innate immunity while avoiding T cell-related side effects commonly seen in other therapies.
- High-affinity CD16A targeting
- Reduced serum IgG competition
- Versatile multi-tumor targeting
- Clinical safety and efficacy data
TriKE Platform
Trispecific Natural Killer Engagers (TriKEs) represent our advanced solution for overcoming NK cell therapy limitations. These molecules combine tumor targeting, NK cell engagement via CD16, and cytokine stimulation (IL-15 or IL-21) to enhance NK cell expansion, survival, and function within tumor microenvironments.
- Three-way engagement design
- Integrated cytokine support
- Enhanced NK cell proliferation
- Adaptable for solid tumors
NKp46-based NKCE Platform
Our Natural Killer Cell Engager (NKCE) platform utilizes trifunctional antibodies targeting the activating NK cell receptors NKp46 and CD16. This innovative approach creates multifunctional antibodies that bind tumor antigens while simultaneously engaging NK cells for enhanced anti-tumor activity.
- Multi-target engagement (tumor antigen, NKp46, CD16)
- Superior killing potency vs. traditional mAbs
- Effective against various tumor types
- Minimal off-target cytotoxicity
